224 related articles for article (PubMed ID: 35173276)
1. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
Nasir Kansestani A; Zare ME; Tong Q; Zhang J
Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
3. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
4. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer.
Turvill J; Mellen S; Jeffery L; Bevan S; Keding A; Turnock D
Scand J Gastroenterol; 2018 Dec; 53(12):1526-1534. PubMed ID: 30621475
[TBL] [Abstract][Full Text] [Related]
6. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
7. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
9. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
[TBL] [Abstract][Full Text] [Related]
11. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients.
Widlak MM; Thomas CL; Thomas MG; Tomkins C; Smith S; O'Connell N; Wurie S; Burns L; Harmston C; Evans C; Nwokolo CU; Singh B; Arasaradnam RP
Aliment Pharmacol Ther; 2017 Jan; 45(2):354-363. PubMed ID: 27910113
[TBL] [Abstract][Full Text] [Related]
18. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.
Ye X; Huai J; Ding J
Turk J Gastroenterol; 2018 Jul; 29(4):397-405. PubMed ID: 30249553
[TBL] [Abstract][Full Text] [Related]
20. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
Högberg C; Karling P; Rutegård J; Lilja M
Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]